John Crowley, CEO, Amicus Therapeutics is set to deliver a unique presentation at this years World #OrphanDrug Congress in Geneva.
John’s approach to #clinicaltrialdesign during the development of orphan drugs has involved patient advisory boards and utilised the strengths of patient groups to assist in clinical trial design. Hear and learn best practice for proving the safety and efficacy of a rare disease treatment during the #clinicaltrial phase of development.
His unique perspective and subsequent success in developing treatments for rare diseases has led to significant global recognition and inspired the film and literacy industries.
For more information on orphan drugs and #rarediseases and to view all other members of the elite speaking faculty click here.